Axsome Therapeutics/$AXSM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Ticker

$AXSM
Primary listing

Industry

Pharmaceuticals

Employees

712

ISIN

US05464T1043

AXSM Metrics

BasicAdvanced
$5.5B
-
-$5.77
0.45
-

What the Analysts think about AXSM

Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.

Bulls say / Bears say

Axsome's flagship product, AUVELITY, has demonstrated strong market adoption, with prescriptions increasing by approximately 17% quarter-over-quarter in Q3 2024, indicating robust demand and potential for sustained revenue growth. (Investing.com)
The company's pipeline includes promising candidates like AXS-05 for Alzheimer's disease agitation and AXS-07 for acute migraines, with analysts projecting peak sales of up to $1.2 billion for AXS-05, suggesting significant future revenue streams. (Investing.com)
Analysts have a consensus 'Strong Buy' rating for AXSM stock, with a 12-month price target of $171.65, representing a potential upside of approximately 62.79% from the current price. (StockAnalysis.com)
Axsome reported a net loss of $287.22 million in 2024, a 20.1% increase from the previous year, indicating ongoing financial challenges despite revenue growth. (StockAnalysis.com)
The company's debt-to-equity ratio stands at 86.42%, suggesting a high level of leverage that could pose risks if revenue growth does not meet expectations. (TipRanks.com)
Despite strong revenue growth, Axsome's return on equity (ROE) is -5.04%, reflecting inefficiencies in generating profit from shareholders' equity. (TipRanks.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

AXSM Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AXSM Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AXSM

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs